FDA Panel Rejects Pimavanserin for Alzheimer's Psychosis
An FDA advisory panel has rejected the atypical antipsychotic pimavanserin for the treatment of Alzheimer’s disease psychosis.
Source: medscape.com
Page 17 - Antipsychotics News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Antipsychotics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Antipsychotics Today - Breaking & Trending Today
Lower-Dose Antipsychotics Benefit Patients with Schizophrenia
Patients with refractory schizophrenia in long-term forensic facilities show significant stabilization after reduced doses of long-acting injectable antipsychotics, new research suggests.
Source: medscape.com
Industry Corruption in Systematic Review for Injectable Antipsychotics
Researchers highlight how systematic reviews are compromised by pharmaceutical industry ties by exposing a study of injectable antipsychotics.
Source: madinamerica.com
High-Dose Antipsychotics Effective in Refractory Schizophrenia
Patients with severe schizophrenia and resistance to standard doses of second-generation antipsychotics show significant improvement and tolerance for higher maintenance doses, new research suggests.
Source: medscape.com
Discontinuation of Antipsychotics Improves Cognitive Functioning
In people with schizophrenia, stopping antipsychotics does not worsen cognitive functioning; instead, it may actually improve cognition.
Source: madinamerica.com